GlassScriptPhysician profile
Corey M Whitesides
NPI 1689019614
$15,492.17
in general payments reported to CMS, 2019-2025
30 companies · $7,472 in 2025
The $7,472 reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.09 · 2022: $1,959 · 2023: $3,020 · 2024: $2,982 · 2025: $7,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,091 · Consulting Fee: $3,600 · Travel and Lodging: $1,199 · Education: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,090.95 |
| Consulting Fee | $3,600.00 |
| Travel and Lodging | $1,199.36 |
| Education | $584.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $7,314.39 | 2022-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $2,066.15 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $1,579.89 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $992.48 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $825.13 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $644.04 | 2022-2025 | Dupixent, Libtayo |
| Ucb, INC. | $375.40 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $259.67 | 2022-2025 | |
| Pfizer INC. | $237.07 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $197.38 | 2022-2024 | |
| Leo Pharma INC. | $147.18 | 2022-2025 | Adbry, Anzupgo |
| Janssen Scientific Affairs, LLC | $121.50 | 2022-2023 | Tremfya |
| Amgen INC. | $114.89 | 2023-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.57 | 2022-2025 | Spevigo |
| Incyte Corporation | $91.45 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $54.11 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Merz North America, INC. | $44.31 | 2023 | Xeomin |
| Convatec INC. | $41.12 | 2024 | |
| Fresenius Kabi USA, LLC | $40.92 | 2023 | Idacio |
| Biofrontera INC. | $39.34 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Vericel Corporation | $35.57 | 2021 | |
| Organon LLC | $28.04 | 2024-2025 | Vtama |
| Ani Pharmaceuticals, INC. | $23.35 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $20.04 | 2025 | Acthar |
| Botanix Sb INC | $19.69 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $19.44 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $18.70 | 2025 | Aklief |
| Organogenesis INC. | $17.42 | 2024 | |
| Dermavant Sciences, INC. | $15.51 | 2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $15.42 | 2024 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Whitesides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.